Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism
5 years ago

Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database

M. Bertolini, H. Wang, L. Tong, L.F. Meneghini, C. Pan, E. Lew
Aim To evaluate the effect of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on clinical and economic outcomes in patients with type 2 diabetes (T2D). Methods We conducted a retrospective observational claims study using IMPACTTM, in adult patients with T2D who initiated basal insulin between 1 January 2005 and 31 December 2012 with or without OADs, but remained uncontrolled (glycated haemoglobin [HbA1c] ≥7.0%). Patients were categorized into three groups: early, delayed, and no intensification with a GLP-1 RA. We evaluated changes from baseline to 12 months’ follow-up for HbA1c level, rate of hypoglycaemic events, and healthcare costs, and assessed the association between baseline patient characteristics and subsequent treatment intensification. Results 139 (9.0% of 1552 eligible patients) met the criteria for inclusion in the early intensification group, 588 (37.9%) in the delayed intensification group, and 825 (53.2%) in the no intensification group. Mean baseline HbA1c values were 9.16%, 9.07%, and 9.34%, respectively. At follow-up, delayed intensification was associated with significantly smaller decreases in HbA1c from baseline (−0.68%) compared with early intensification (−1.01%). Rates of overall hypoglycaemia was numerically greater in delayed intensification group than in early intensification group (0.26 vs 0.06 events/patient-years of exposure, respectively).The change in semi-annual total healthcare costs was greater in the no intensification group (+US$5266) compared with the early intensification (−US$560) and delayed intensification groups (+US$1943). Conclusions Timely addition of a GLP-1 RA to therapy for patients with T2D not adequately controlled on basal insulin is associated with better clinical and economic outcomes.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/dom.13156

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.